Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis
Peter J. Darlington(Concordia University), Amit Bar‐Or(University of Pennsylvania), Mark S. Freedman(University of Ottawa), Harold Atkins(University of Ottawa), Morgan E. Roberts(Montreal Neurological Institute and Hospital), Jean-Sébastien Doucet(Montreal Neurological Institute and Hospital), Marie‐Noëlle Boivin(Montreal Neurological Institute and Hospital), Lama Fawaz(Montreal Neurological Institute and Hospital), Brandon Stopnicki(Concordia University), Tarik Touil(Montreal Neurological Institute and Hospital), Nathalie Arbour(Centre Hospitalier de l’Université de Montréal)
Cited by 77
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k